A noticeable trend among children presenting at sleep clinics is the widespread use of melatonin, with many patients having previously used or currently taking the supplement. While melatonin is recognized as a valuable tool in addressing pediatric sleep disorders and is often perceived as safe due to its natural origin, a growing concern is emerging regarding its frequent and, at times, unsupervised administration. This trend is mirrored by an increase in the use of magnesium supplements for sleep, for which scientific evidence remains limited.
The exact prevalence of melatonin use in children is difficult to pinpoint. However, a 2022 study published in JAMA estimated that adult melatonin use had tripled between 2005 and 2018, with users increasingly opting for higher doses. The aggressive marketing of melatonin products specifically for children further amplifies concerns that its widespread availability might be leading some parents to view it as a convenient shortcut to establishing healthy sleep habits. Anecdotal evidence, such as a father’s review on Amazon quoted in a Wall Street Journal article, highlights this sentiment: "OK, yes, as parents my wife and I should do a better job starting the bedtime routine earlier, turning off the TV earlier, limiting sweets, etc., etc. Well, for whatever reason, this is not our strong suit. This 1 mg light dosage of melatonin is very helpful winding our kids down and getting them ready for bed."
Escalating Melatonin Consumption Among Children
Data from various sources indicates a significant uptick in melatonin consumption among children. A New York Times article from May 2020, titled "Parents Are Relying on Melatonin to Help Their Kids Sleep. Should They?", reported an 87% increase in overall melatonin sales in the year preceding March 2020. A survey conducted by the Times revealed that among 933 parents with children under 18, over half had given their children melatonin at some point, with one-third reporting a history of sleep difficulties in the past year.
More recent international data paints an even starker picture. Scandinavia has witnessed an almost 500% surge in melatonin prescriptions. In the United States, melatonin has become the most common cause of overdose in pediatric emergency rooms and a leading reason for calls to poison control centers, underscoring the global nature of this phenomenon.
Understanding Melatonin: Its Role and Mechanisms
Melatonin is a hormone naturally produced by the pineal gland in the brain. It functions as a chronobiotic agent, regulating the body’s circadian rhythm or internal clock, and as a hypnotic, which at higher doses can induce sleep. While its hypnotic effect is often the primary reason for its use in sleep aids, it is important to note that this effect is not universal; however, its chronobiotic effect is present in all individuals.
The natural increase in melatonin levels in the body, typically one to three hours before sleep onset, is known as the "dim light melatonin onset" (DLMO). This physiological signal is crucial for scheduling sleep and marking the end of the circadian system’s wakefulness signal. Children experiencing insomnia may be administered melatonin after their designated bedtime has passed, indicating their bodies are not yet biologically prepared for sleep. This underscores why behavioral interventions like "bedtime fading" can be effective, as they align with the child’s natural sleep-wake cycle. The clinical doses of melatonin used, ranging from 0.5 mg to 10 mg or higher, significantly exceed the amounts naturally secreted by the body.
Effectiveness of Melatonin for Pediatric Sleep Issues
Studies generally indicate that melatonin can help children fall asleep more quickly and increase overall sleep duration. However, the research landscape for pediatric sleep aids, including melatonin, is characterized by a scarcity of comprehensive data. Most studies involve small participant groups and short follow-up periods. A significant contributing factor to this data gap is that in the United States, melatonin is regulated as a food supplement by the FDA, not as a pharmaceutical. This means that large pharmaceutical companies are not incentivized to fund extensive, long-term clinical trials.
A meta-analysis published in 2023, combining data from 419 children, reported an approximate 30-minute increase in total sleep time overnight, with about 18 minutes of this attributed to a reduction in the time taken to fall asleep (sleep latency). Notably, this study did not find any improvement in daytime functioning, and the treatment group experienced an increase in adverse events compared to the placebo group.
The International Pediatric Sleep Association (IPSA) provides valuable resources, including parent guides and literature reviews on melatonin use in both typically developing children and those with autism. Their recommendations suggest that melatonin typically results in about 30 minutes of additional sleep per night, primarily by shortening the time to fall asleep. This effect is consistent across various studies in children, but it is crucial to understand that melatonin is not a panacea for all sleep problems.
Melatonin Use in Specific Pediatric Populations
-
Chronic Sleep-Onset Insomnia in Typically Developing Children: Difficulty falling asleep is a common issue. Chronic insomnia is defined by difficulties falling or staying asleep at least three times per week for three months or more, leading to sleep dissatisfaction or daytime impairment. The aforementioned 2023 meta-analysis by Edemann-Callesen found a modest benefit in sleep latency but also an increase in adverse events. The 2025 IPSA position paper offers specific recommendations for this age group.
-
Autism Spectrum Disorder (ASD): Sleep disturbances are prevalent in children with ASD, manifesting as prolonged sleep onset, reduced nighttime sleep, and difficulties with nocturnal and early morning awakenings. Some research suggests that children with ASD may have lower melatonin levels and less variation in their secretion patterns. Melatonin has shown promise in helping these children fall asleep more easily and increase total sleep time. A 2025 meta-analysis by Yang et al. indicated that melatonin’s most significant effects were on sleep efficiency and total sleep time, with greater benefits observed in older children. The effectiveness of melatonin can diminish over time, and higher doses appear to be more efficacious. A 2017 trial investigating a time-release melatonin preparation (PedPRM) demonstrated a significant increase in total sleep time and a reduction in sleep latency. This formulation is available in Europe as Slenyto but is not currently FDA-approved in the USA. The 2024 IPSA recommendations for melatonin use in children with ASD provide further guidance.
-
Attention-Deficit/Hyperactivity Disorder (ADHD): ADHD is frequently associated with sleep problems, which can, in turn, exacerbate attentional issues. Studies suggest that up to 70% of children with ADHD experience sleep difficulties, including prolonged sleep onset, altered sleep architecture, and daytime sleepiness. A 2024 review by Cortese on managing sleep issues in ADHD highlighted two randomized controlled trials showing benefits. A 2024 systematic review by Larsson noted a decrease in sleep latency and improved sleep efficiency but no significant improvements in quality of life or daytime ADHD symptoms.
-
Delayed Sleep-Phase Syndrome (DSPS): This disorder, common in adolescents, involves a significant shift in the natural sleep period to later times, making it difficult to adhere to early school schedules. Melatonin plays a crucial role in managing DSPS. Administering small doses several hours before the desired sleep onset, alongside light exposure management and sleep hygiene practices, can effectively shift sleep periods earlier. This condition demonstrates one of the clearest benefits of melatonin.
-
Children with Neurodevelopmental Delay: Insomnia is common in children with neurodevelopmental delays, and melatonin may offer assistance. However, in some cases, melatonin use has been associated with persistently high daytime melatonin levels and subsequent daytime sleepiness. A 2023 review by Edemann-Callesen examined melatonin’s use in a mixed group of conditions, finding a modest increase in total sleep time primarily due to reduced latency, but no significant improvement in subjective sleep quality or daytime functioning.
-
Blindness: Children with blindness may experience disrupted sleep-wake cycles due to the absence of light cues regulating their circadian rhythm. While small trials in adults have shown some benefit, the data for children remains very limited.
-
Eczema: The discomfort associated with eczema can lead to insomnia and non-restorative sleep. Some research suggests that children with eczema may have lower melatonin levels, and a recent trial indicated that melatonin might be helpful.
Potential Concerns and Risks Associated with Melatonin
Despite its perceived safety, several concerns warrant attention regarding melatonin use in children:
- Theoretical Side Effects: Prolonged or excessive melatonin administration could lead to persistently elevated blood melatonin levels throughout the day, potentially causing daytime sleepiness. The long-term effects of such elevations are not fully understood.
- Regulatory Oversight: Unlike pharmaceuticals, melatonin is regulated as a dietary supplement by the FDA in the U.S. This means less rigorous oversight regarding safety and efficacy. Long-term studies on children using melatonin have largely relied on parental reports rather than biochemical testing. Dr. David Kennaway, a physician from Australia, has highlighted the inadequacy of long-term safety data, noting that melatonin is not registered for use in children and lacks rigorous long-term safety studies. He also points out that melatonin is used as a veterinary drug to alter the reproductive cycles of sheep and goats.
- Product Labeling and Quality: The labeling of melatonin preparations can be misleading. For instance, a liquid product labeled as "1 mg" might actually contain 0.25 mg per dropperful, requiring parents to consult external resources for accurate dosing information. This lack of clarity can contribute to unintentional overdosing. While a 2020 study of a long-acting melatonin formulation (PedPRM) followed 80 children for two years and found no evidence of adverse effects on weight, height, BMI, or sexual development, this remains one of the few long-term safety studies, and more research is needed. The U.S. Pharmacopeial Convention (USP) offers a verification program that can indicate a product meets certain quality standards, which may offer a degree of reassurance.
Navigating Melatonin Use: Guidance for Parents and Healthcare Providers
For parents whose children are already taking melatonin, the advice is generally not to panic, as concrete evidence of significant harm is limited. However, if melatonin was initiated without physician consultation, it is strongly recommended to discuss its necessity with the child’s pediatrician. For children on long-term melatonin who are sleeping well, a gradual dose reduction can be considered to assess if it remains necessary.
The emphasis should always be on prioritizing robust sleep hygiene practices, including a consistent and high-quality bedtime routine, limiting screen time at least an hour before bed, and establishing an appropriate sleep schedule. Melatonin should ideally be used as needed rather than nightly, and its use should be periodically re-evaluated. The 2025 IPSA recommendations suggest limiting melatonin use to 3-6 months and attempting breaks from the supplement.
Dosing and Administration Considerations
Dosing melatonin can be complex, as its effects are influenced by the timing of administration relative to the child’s usual sleep schedule. A small dose given a few hours before bedtime may be more effective than a larger dose administered at bedtime. Generally, 30-60 minutes before the child’s bedtime is considered optimal, although earlier administration might be beneficial in some cases.
The 2025 IPSA guidelines provide age-based dosing recommendations, suggesting starting at 0.5 mg and increasing by 0.5 mg weekly until improvement is observed or the maximum dose is reached. A melatonin dosing calculator can assist parents and healthcare providers in selecting the safest dosage for their child.
Crucially, melatonin should not be considered a substitute for sound sleep hygiene practices. It should be used in conjunction with a strong bedtime routine, appropriate light exposure management, and a consistent sleep schedule.
The Takeaway: A Balanced Approach to Melatonin
The decision to use melatonin for a child’s sleep issues is often made after considerable deliberation and attempts at behavioral interventions. Given the limited availability of FDA-approved insomnia medications for children, melatonin has become a common option in pediatric practice, proving helpful for many children and families. While acknowledging the concerns raised about its long-term safety and regulatory status, the profound impact of chronic sleep deprivation on children and families cannot be ignored.
Pediatricians should always investigate other potential causes of insomnia, such as restless leg syndrome, before considering medication. The ultimate goal is to help children achieve adequate sleep with minimal reliance on medication. For some children, particularly those with autism or developmental issues, medication may be a necessary component of their sleep management plan. Melatonin can be a suitable option when:
- Behavioral interventions and sleep hygiene practices have been thoroughly implemented and have proven insufficient.
- The child has a diagnosed sleep disorder for which melatonin is considered an appropriate treatment.
- The potential benefits of improved sleep are weighed against the known and theoretical risks, in consultation with a healthcare professional.
In cases where sleep difficulties arise suddenly, it is important to consider the possibility of a sleep regression, for which specific strategies exist.
Special thanks are extended to Bob Young R.Ph for his contributions to the initial development of this article.
Originally published April 2026. Last reviewed/updated by Dr. Craig Canapari, MD in April 2026.
